抗血管生成药物作为晚期上皮卵巢癌的维持策略
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
Article Outline
- Abstract
- 1. Introduction
- 1.1. Bevacizumab in ovarian cancer
- 1.2. Novel antiangiogenic agents in gynecologic malignancies
- 1.2.1. Nintedanib
- 1.2.2. Sorafenib
- 1.2.3. Pazopanib
- 1.2.4. Cediranib
- 1.2.5. AMG 386
- 1.3. Current controversies surrounding antiangiogenic maintenance therapy for ovarian cancer
- 2. Conclusion
- Conflict of interest statement
- Role of the funding source
- Reviewers
- Acknowledgements
- References
- Biography
- Copyright
Abstract
Bevacizumab is the first antiang
学科代码:肿瘤学 关键词:Angiogenesis inhibitors Epithelial ovarian cancer Vascular endothelial growth fa Molecular targeted therapy Bevacizumab
来源: Critical Reviews In Oncology Hematology
来源: Critical Reviews In Oncology Hematology
顶一下(0)
- 您可能感兴趣的文章
-